PRRT Indications Guidelines: Who to Treat

When:  Sep 5, 2019 from 2:00 PM to 3:00 PM (ET)
Objectives: Understand where 177Lutetium-dotatate might fit within the neuroendocrine tumor treatment landscape Understand impact of PRRT on key endpoints including progression-free survival and health-related quality of life Identify potential risks of 177Lutetium-dotatate, including long-term myelotoxicity Discuss relative and absolute contraindications to treatment